Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma.

Author: AlexanderM, BouletL-P, ChapmanK R, D'UrzoA D, EngelstätterR, MehraS, OedekovenC, PatelP

Paper Details 
Original Abstract of the Article :
Inhaled corticosteroids (ICS) are recommended therapy for persistent asthma, although side effects can limit appropriate use. Ciclesonide, a novel ICS, is activated in the lung, thereby reducing systemic activity and side effects. This 12-week, double-blind, randomized, parallel-group, placebo-contr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/j.1398-9995.2004.00750.x

データ提供:米国国立医学図書館(NLM)

Maintaining Asthma Control with Ciclesonide

Asthma, a chronic respiratory condition, affects millions worldwide. This study investigates the efficacy and safety of ciclesonide, a novel inhaled corticosteroid (ICS), in maintaining asthma control in adults with persistent asthma. The researchers conducted a 12-week, double-blind, randomized, placebo-controlled study to evaluate the effectiveness of ciclesonide compared to placebo.

A Novel Approach to Asthma Management

The study found that ciclesonide was effective in maintaining asthma control in adults with persistent asthma. The researchers concluded that ciclesonide, with its unique lung-specific activation, offers a promising approach to managing asthma while minimizing the risk of systemic side effects.

Improved Asthma Control and Quality of Life

This research suggests that ciclesonide could lead to improved asthma control and quality of life for patients with persistent asthma. The availability of a well-tolerated and effective ICS with reduced systemic side effects could significantly benefit patients by improving their ability to manage their condition and live active lives.

Dr.Camel's Conclusion

This study highlights the importance of innovation in the field of asthma management. The development of novel ICSs like ciclesonide, with their targeted delivery and reduced systemic side effects, offers hope for improving asthma control and quality of life for patients. Like a skilled camel navigating a sandstorm, these advancements are helping to clear the path for patients to breathe easier and live fuller lives.

Date :
  1. Date Completed 2005-06-20
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15679718

DOI: Digital Object Identifier

10.1111/j.1398-9995.2004.00750.x

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.